Search Result

Results for "

aciduria

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylin Receptor (1) Amyloid-β (1) Antibiotic (1) ATP Synthase (7) Bacterial (1) Calcineurin (1) CD38 (1) CGRP Receptor (2) Chemerin Receptor (1) Drug Derivative (3) Drug Metabolite (1) Endogenous Metabolite (37) Ephrin Receptor (1) Ferroportin (1) Fungal (1) GABA Receptor (1) GCGR (13) GLP Receptor (16) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (11) MARCKS (2) Melanocortin Receptor (1) Mitochondrial Metabolism (2) MOFs (1) mTOR (4) Na+/K+ ATPase (2) Natriuretic Peptide Receptor (NPR) (1) Neuropeptide Y Receptor (1) Opioid Receptor (1) Oxidative Phosphorylation (1) PD-1/PD-L1 (2) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (1) Phospholipase (1) PKC (2) Ras (1) Reactive Oxygen Species (ROS) (10) Reference Standards (9) Renin (1) RXFP Receptor (1) Vasopressin Receptor (3)
By Research Areas:	Cancer (14) Cardiovascular Disease (4) Endocrinology (1) Infection (2) Inflammation/Immunology (16) Metabolic Disease (58) Neurological Disease (19)

By Targets:

Amylin Receptor (1)

Amyloid-β (1)

Antibiotic (1)

ATP Synthase (7)

Bacterial (1)

Calcineurin (1)

CD38 (1)

CGRP Receptor (2)

Chemerin Receptor (1)

Drug Derivative (3)

Drug Metabolite (1)

Endogenous Metabolite (37)

Ephrin Receptor (1)

Ferroportin (1)

Fungal (1)

GABA Receptor (1)

GCGR (13)

GLP Receptor (16)

HMG-CoA Reductase (HMGCR) (1)

Isotope-Labeled Compounds (11)

MARCKS (2)

Melanocortin Receptor (1)

Mitochondrial Metabolism (2)

MOFs (1)

mTOR (4)

Na+/K+ ATPase (2)

Natriuretic Peptide Receptor (NPR) (1)

Neuropeptide Y Receptor (1)

Opioid Receptor (1)

Oxidative Phosphorylation (1)

PD-1/PD-L1 (2)

Peptide-Drug Conjugates (PDCs) (1)

Phosphatase (1)

Phospholipase (1)

PKC (2)

Ras (1)

Reactive Oxygen Species (ROS) (10)

Reference Standards (9)

Renin (1)

RXFP Receptor (1)

Vasopressin Receptor (3)

By Research Areas:

Cancer (14)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (16)

Metabolic Disease (58)

Neurological Disease (19)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-113126

3-Hydroxyisobutyric acid	Endogenous Metabolite ATP Synthase	Neurological Disease Metabolic Disease
3-Hydroxyisobutyric acid is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis .

HY-W018035

DL-Glyceric Acid (20% in water) 1 Publications Verification Glyceric Acid (20% in Water,ca.2 mol/L)	Endogenous Metabolite	Metabolic Disease
DL-Glyceric Acid (20% in water) is a metabolite of plants and mammals and exists in two configurations, D and L .

HY-113149A

Argininosuccinic acid disodium	Endogenous Metabolite Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Inflammation/Immunology
Argininosuccinic acid disodium is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid disodium can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid disodium can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid disodium can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-100542

D-α-Hydroxyglutaric acid disodium 4 Publications Verification Disodium (R)-2-hydroxyglutarate	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113038

D-α-Hydroxyglutaric acid 4 Publications Verification (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-113005

Glutarylcarnitine	Endogenous Metabolite	Metabolic Disease
Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-W008820

Glutaric acid	MOFs Endogenous Metabolite	Metabolic Disease
Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-113149

Argininosuccinic acid	Endogenous Metabolite Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Inflammation/Immunology
Argininosuccinic acid is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-113410

3-Methylglutaric acid	Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na ⁺, K ⁺-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na ⁺, K ⁺-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-113285

Ureidopropionic acid 3-Ureidopropionic acid	Oxidative Phosphorylation	Metabolic Disease
Ureidopropionic acid is a mitochondrial respiratory chain complex V inhibitor that selectively inhibits the activity of mitochondrial respiratory chain complex V, with no effect on respiratory chain complexes I-IV or mitochondrial fatty acid β-oxidation. Ureidopropionic acid induces the production of reactive oxygen species, delayed elevation of intracellular calcium concentration, secondary energy-dependent excitotoxicity and neurodegeneration in neurons. Ureidopropionic acid promotes neuropathological changes by impairing mitochondrial energy metabolism, oxidative stress and excitotoxicity pathways. Ureidopropionic acid can be used in studies related to 3-ureidopropionase deficiency and severe propionic aciduria .

HY-128426

Trans-2-butene-1,4-dicarboxylic acid Dihydromuconic acid; trans-β-Hydromuconic acid	Endogenous Metabolite	Metabolic Disease
Trans-2-butene-1,4-dicarboxylic acid (Dihydromuconic acid; trans-β-Hydromuconic acid) is an endogenous metabolite .

HY-W015874

2-Hydroxy-2-methylbutanoic acid	Endogenous Metabolite	Metabolic Disease
2-Hydroxy-2-methylbutanoic acid is a branched-chain fatty acid. 2-Hydroxy-2-methylbutanoic acid accumulates at high levels in the culture supernatants of colorectal cancer-associated bacteria. 2-Hydroxy-2-methylbutanoic acid is also present in the urine of patients with 2-hydroxyglutaric aciduria and maple syrup urine disease .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-W008820S

Glutaric acid-d6 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Glutaric acid-d₆ is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-135700

Mevalonolactone	Calcineurin Ras HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-159681

AASS-IN-1	Others	Metabolic Disease
AASS-IN-1 is a 2-aminoadipic semialdehyde synthase (AASS) inhibitor with a human IC₅₀ of 142 µM. AASS-IN-1 inhibits AASS activity by binding to the LOR domain of AASS. AASS-IN-1 can be used for the research of glutaric aciduria type 1 .

HY-CE02028

Glutaconyl-CoA Glutaconyl-coenzyme A	Endogenous Metabolite	Metabolic Disease
Glutaconyl-CoA (Glutaconyl-coenzyme A) is a key metabolic intermediate in the mitochondrial catabolic pathways of lysine, hydroxylysine and tryptophan. Glutaconyl-CoA competitively inhibits wild-type glutaryl-CoA dehydrogenase (GCDH) with a K_i value of 1.1 µM. Glutaconyl-CoA is generated via the oxidative decarboxylation of glutaryl-CoA catalyzed by GCDH, and is subsequently further metabolized. Glutaconyl-CoA can be used in the research of type I glutaric aciduria .

HY-139427

3-Methylglutaconic acid β-Methylglutaconic acid	GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11273

Urcosimod OK 101	Chemerin Receptor	Neurological Disease Inflammation/Immunology
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .

HY-153476A

GIP/GLP-1 dual receptor agonist-1 sodium	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-W014125

Undecanedioic acid 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Undecanedioic acid is an oral activie nndogenous metabolite. Undecanedioic acid is associated with intercellular matrix macromolecules and specifically with elastin .

HY-P11290

MC4-NN2-0453	Melanocortin Receptor	Metabolic Disease
MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .

HY-W654003

D-α-Hydroxyglutaric acid-d5 disodium Disodium (R)-2-hydroxyglutarate-d₅	Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid-d₅ disodium (Disodium (R)-2-hydroxyglutarate-d₅) is the deuterium labeled D-α-Hydroxyglutaric acid disodium (HY-100542). D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-113005A

Glutarylcarnitine lithium	Endogenous Metabolite	Metabolic Disease
Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes .

HY-113499B

cis-Malonylcarnitine lithium	Drug Metabolite	Others
cis-Malonylcarnitine lithium is an ester compound and a metabolite of Malonyl CoA (HY-115899). The level of cis-Malonylcarnitine lithium is closely related to some diseases, such as malonic aciduria, non-syndromic cleft lip with or without cleft palate, etc .

HY-113377

L-Glyceric acid	Endogenous Metabolite	Metabolic Disease
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2 .

HY-113406

(±)-Hexanoylcarnitine DL-Hexanoylcarnitine	Others	Inflammation/Immunology
(±)-Hexanoylcarnitine exists in human urine and plasma. (±)-Hexanoylcarnitine can be used as a plasma detection indicator in patients with methylmalonic aciduria, propionic acidemia, and medium-chain acyl-CoA dehydrogenase deficiency .

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-W008820R

Glutaric acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Glutaric acid (Standard) is the analytical standard of Glutaric acid. This product is intended for research and analytical applications. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I . In Vitro: Glutaric acid (GA) at concentrations of 1 and 2 mM is able to reduce TRAP measurement by up to 28% in a dose-dependent manner (β=0.77; P<0.001). Furthermore, a significantly inverse correlation is also verified between chemiluminescence and TRAP (β=0.81; P<0.001). Glutaric acid does not alter the activities of Cat and SOD, but strongly inhibits (up to 46%) the activity of GPx even at the lower concentration used (0.5 mM). It is observed that the metabolite inhibits this activity in a dose-dependent manner at concentrations as low as 0.05 mM .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

HY-113005S

Glutarylcarnitine-d9 chloride	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Glutarylcarnitine-d₉ (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-W008820S1

Glutaric acid-d4	Endogenous Metabolite	Metabolic Disease
Glutaric acid-d₄ is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-N5134S5

5'-Guanylic acid-13C10,15N5 dilithium 5'-GMP-13C10,15N5 dilithium; 5'-guanosine monophosphate-13C10,15N5 dilithium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
5'-Guanylic acid- ¹³C₁₀, ¹⁵N₅ (5'-GMP- ¹³C₁₀, ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹³C₁₀, ¹⁵N₅) dilithium is ¹³C and ¹⁵N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

Cat. No.	Product Name	Target	Research Area

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11273

Urcosimod OK 101	Chemerin Receptor	Neurological Disease Inflammation/Immunology
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .

HY-153476A

GIP/GLP-1 dual receptor agonist-1 sodium	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-P11290

MC4-NN2-0453	Melanocortin Receptor	Metabolic Disease
MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .

HY-169089A

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P0014A

Liraglutide acetate	GLP Receptor	Metabolic Disease
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P1614

ZEP-3	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
ZEP-3 is a tetrapeptide derivative with anti-aging activity for the skin. ZEP-3 can inhibit ROS production and alleviate oxidative stress .

HY-P0041A

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-113560

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P10910

Vensemaglutide	GLP Receptor	Metabolic Disease
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .

HY-P11243

EphA4 agonist compound 23	Ephrin Receptor	Neurological Disease
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P10869

dCNP 1 Publications Verification	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-P4837

Ac-Lys-D-Ala-D-lactic acid	Peptides	Others
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P0041

F992	Vasopressin Receptor	Neurological Disease
F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P5161

FC382K10W15	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research .

HY-109166

Amdakefalin	Opioid Receptor	Neurological Disease
Amdakefalin is a μ and δ opioid receptors agonist with analgesic effects .

HY-P11279

TC2	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .

HY-P5161A

FC382K10W15 TFA	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P10381

palm11-TTDS-PrRP31	Peptides	Others
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC₅₀: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .

HY-P2595

SKF 103784	Endogenous Metabolite	Cardiovascular Disease
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .

HY-P10881

Ganipatide	Peptide-Drug Conjugates (PDCs)	Metabolic Disease
Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .

HY-P11759

Myr-transportan-Cys	Drug Derivative	Cancer
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .

HY-N17580

Lyciumin D	Renin	Cardiovascular Disease
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .

HY-P11604

C16 acid-I-{Lys(C10 diacid)}-KQELRRIGDEF	Phosphatase	Inflammation/Immunology
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC₅₀ values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113126

3-Hydroxyisobutyric acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite ATP Synthase
3-Hydroxyisobutyric acid is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis .

HY-W018035

DL-Glyceric Acid (20% in water) 1 Publications Verification Glyceric Acid (20% in Water,ca.2 mol/L)	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
DL-Glyceric Acid (20% in water) is a metabolite of plants and mammals and exists in two configurations, D and L .

HY-113149A

Argininosuccinic acid disodium	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS)
Argininosuccinic acid disodium is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid disodium can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid disodium can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid disodium can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-100542

D-α-Hydroxyglutaric acid disodium 4 Publications Verification Disodium (R)-2-hydroxyglutarate	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification Cancer	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113038

D-α-Hydroxyglutaric acid 4 Publications Verification (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Classification of Application Fields Neurological Disease Anti-aging Endocrine diseases Endogenous metabolite Immune System Disorder Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Disease Research Fields Inflammation/Immunology Cancer Source Classification	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113005

Glutarylcarnitine	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-W008820

Glutaric acid	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	MOFs Endogenous Metabolite
Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-113149

Argininosuccinic acid	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS)
Argininosuccinic acid is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc .

HY-113410

3-Methylglutaric acid	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields Cardiovascular System Disorder Source Classification	Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species (ROS)
3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na ⁺, K ⁺-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na ⁺, K ⁺-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .

HY-113285

Ureidopropionic acid 3-Ureidopropionic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields	Oxidative Phosphorylation
Ureidopropionic acid is a mitochondrial respiratory chain complex V inhibitor that selectively inhibits the activity of mitochondrial respiratory chain complex V, with no effect on respiratory chain complexes I-IV or mitochondrial fatty acid β-oxidation. Ureidopropionic acid induces the production of reactive oxygen species, delayed elevation of intracellular calcium concentration, secondary energy-dependent excitotoxicity and neurodegeneration in neurons. Ureidopropionic acid promotes neuropathological changes by impairing mitochondrial energy metabolism, oxidative stress and excitotoxicity pathways. Ureidopropionic acid can be used in studies related to 3-ureidopropionase deficiency and severe propionic aciduria .

HY-128426

Trans-2-butene-1,4-dicarboxylic acid Dihydromuconic acid; trans-β-Hydromuconic acid	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Trans-2-butene-1,4-dicarboxylic acid (Dihydromuconic acid; trans-β-Hydromuconic acid) is an endogenous metabolite .

HY-W015874

2-Hydroxy-2-methylbutanoic acid	Structural Classification Other disease Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
2-Hydroxy-2-methylbutanoic acid is a branched-chain fatty acid. 2-Hydroxy-2-methylbutanoic acid accumulates at high levels in the culture supernatants of colorectal cancer-associated bacteria. 2-Hydroxy-2-methylbutanoic acid is also present in the urine of patients with 2-hydroxyglutaric aciduria and maple syrup urine disease .

HY-135700

Mevalonolactone	Structural Classification Microorganisms Other Phenylpropanoids Phenylpropanoids Source Classification	Calcineurin Ras HMG-CoA Reductase (HMGCR)
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-W014125

Undecanedioic acid 1 Publications Verification	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Undecanedioic acid is an oral activie nndogenous metabolite. Undecanedioic acid is associated with intercellular matrix macromolecules and specifically with elastin .

HY-113005A

Glutarylcarnitine lithium	Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes .

HY-113377

L-Glyceric acid	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2 .

HY-113406

(±)-Hexanoylcarnitine DL-Hexanoylcarnitine	Natural Products Animals Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Others
(±)-Hexanoylcarnitine exists in human urine and plasma. (±)-Hexanoylcarnitine can be used as a plasma detection indicator in patients with methylmalonic aciduria, propionic acidemia, and medium-chain acyl-CoA dehydrogenase deficiency .

HY-W008820R

Glutaric acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Glutaric acid (Standard) is the analytical standard of Glutaric acid. This product is intended for research and analytical applications. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I . In Vitro: Glutaric acid (GA) at concentrations of 1 and 2 mM is able to reduce TRAP measurement by up to 28% in a dose-dependent manner (β=0.77; P<0.001). Furthermore, a significantly inverse correlation is also verified between chemiluminescence and TRAP (β=0.81; P<0.001). Glutaric acid does not alter the activities of Cat and SOD, but strongly inhibits (up to 46%) the activity of GPx even at the lower concentration used (0.5 mM). It is observed that the metabolite inhibits this activity in a dose-dependent manner at concentrations as low as 0.05 mM .

HY-113005R

Glutarylcarnitine (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Glutarylcarnitine (Standard) is the analytical standard of Glutarylcarnitine. This product is intended for research and analytical applications. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-113377A

L-Glyceric acid sodium	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2 .

HY-W016813R

trans-Aconitic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Endogenous metabolite Cancer Source Classification	Reference Standards Endogenous Metabolite
trans-Aconitic acid (Standard) is the analytical standard of trans-Aconitic acid. This product is intended for research and analytical applications. trans-Aconitic acid is present in normal human urine, and it has been suggested that is present in larger amounts with Reye's syndrome and organic aciduria. trans-Aconitic acid is a substrate of enzyme trans-aconitate 2-methyltransferase.

HY-128426R

Trans-?2-?butene-?1,?4-?dicarboxylic acid (Standard) Dihydromuconic acid (Standard); trans-β-Hydromuconic acid (Standard)	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Trans-2-butene-1,4-dicarboxylic acid (Standard) is the analytical standard of Trans-2-butene-1,4-dicarboxylic acid. This product is intended for research and analytical applications. Trans-2-butene-1,4-dicarboxylic acid (Dihydromuconic acid; trans-β-Hydromuconic acid) is an endogenous metabolite[1][2].

HY-113126R

3-Hydroxyisobutyric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite ATP Synthase Reference Standards
3-Hydroxyisobutyric acid (Standard) is the analytical standard of 3-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 3-Hydroxyisobutyric acid is an important interorgan metabolite, an intermediate in the pathways of l-valine and thymine and a good gluconeogenic substrate.

HY-113410R

3-Methylglutaric acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Source Classification	Reference Standards Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species (ROS)
3-Methylglutaric acid (Standard) is the analytical standard of 3-Methylglutaric acid (HY-113410). This product is intended for research and analytical applications. 3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na ⁺, K ⁺-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na ⁺, K ⁺-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .

HY-100542R

D-α-Hydroxyglutaric acid disodium (Standard) Disodium (R)-2-hydroxyglutarate (Standard)	Structural Classification Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of D-α-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113005AR

Glutarylcarnitine lithium (Standard)	Structural Classification Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Glutarylcarnitine (lithium) (Standard) is the analytical standard of Glutarylcarnitine (lithium). This product is intended for research and analytical applications. Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes .

HY-W015874R

2-Hydroxy-2-methylbutanoic acid (Standard)	Structural Classification Other disease Ketones, Aldehydes, Acids Disease markers Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
2-Hydroxy-2-methylbutanoic acid (Standard) is the analytical standard of 2-Hydroxy-2-methylbutanoic acid. This product is intended for research and analytical applications. 2-Hydroxy-2-methylbutanoic acid, an unusual metabolite, is associated with 2-hydroxyglutaric aciduria and maple syrup urine disease.

HY-N17580

Lyciumin D	Structural Classification Lycium barbarum L. Cyclopeptides Phenols Solanaceae Plants Source Classification	Renin
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .

Cat. No.	Product Name	Chemical Structure

HY-W008820S

Glutaric acid-d6 1 Publications Verification
Glutaric acid-d₆ is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-W654003

D-α-Hydroxyglutaric acid-d5 disodium

D-α-Hydroxyglutaric acid-d₅ disodium (Disodium (R)-2-hydroxyglutarate-d₅) is the deuterium labeled D-α-Hydroxyglutaric acid disodium (HY-100542). D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113005S

Glutarylcarnitine-d9 chloride
Glutarylcarnitine-d₉ (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.

HY-W008820S1

Glutaric acid-d4
Glutaric acid-d₄ is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

HY-N5134S5

5'-Guanylic acid-13C10,15N5 dilithium

5'-Guanylic acid- ¹³C₁₀, ¹⁵N₅ (5'-GMP- ¹³C₁₀, ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹³C₁₀, ¹⁵N₅) dilithium is ¹³C and ¹⁵N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-N5134S2

5'-Guanylic acid-15N5 dilithium
5'-Guanylic acid- ¹⁵N₅ (5'-GMP- ¹⁵N₅ dilithium; 5'-guanosine monophosphate- ¹⁵N₅) dilithium is ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S1

5'-Guanylic acid-13C10 dilithium
5'-Guanylic acid- ¹³C₁₀ (5'-GMP- ¹³C₁₀ dilithium; 5'-guanosine monophosphate- ¹³C₁₀) dilithium is ¹³C-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-N5134S3

5'-Guanylic acid-d12 dilithium
5'-Guanylic acid-d₁₂ (5'-GMP-d₁₂ dilithium; 5'-guanosine monophosphate-d₁₂) dilithium is deuterium labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-W779800

D-α-Hydroxyglutaric acid-13C5 disodium

D-α-Hydroxyglutaric acid- ¹³C₅ disodium is the ¹³C-labeled D-α-Hydroxyglutaric acid (HY-113038). D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-N5134S4

5'-Guanylic acid-15N5,d12 dilithium

5'-Guanylic acid- ¹⁵N₅,d₁₂ (5'-GMP- ¹⁵N₅,d₁₂ dilithium; 5'-guanosine monophosphate- ¹⁵N₅,d₁₂) dilithium is deuterium and ¹⁵N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

HY-W008820S2

Glutaric acid-d2
Glutaric acid-d₂ is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

aciduria

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products